Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, Hu Y. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal Of Molecular Sciences 2023, 24: 16056. PMID: 38003245, PMCID: PMC10671096, DOI: 10.3390/ijms242216056.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BispecificAntineoplastic AgentsCell Line, TumorHumansImmunoconjugatesMiceReceptor, ErbB-2Xenograft Model Antitumor AssaysConceptsHuman epidermal growth factor receptor 2Low HER2 expressionHER2 expressionSortilin 1Antitumor efficacyEpidermal growth factor receptor 2MDA-MB-231 xenograft mouse modelTumor cellsGrowth factor receptor 2High HER2 expressionTreatment of patientsXenograft mouse modelFactor receptor 2Bispecific antibody-drug conjugatesAntibody-drug conjugatesTreatment of tumorsExpression tumorsMouse modelReceptor 2Bispecific antibody drugsToxic payloadsBispecific antibodiesTumorsNormal tissuesAntibody drugs